14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

作者： M. Peeters , T. Price , Y. Hotko , A. Cervantes , M. Ducreux

DOI: 10.1016/S1359-6349(09)72049-X

关键词: Phases of clinical research 、 FOLFIRI 、 Colorectal cancer 、 Oncology 、 Panitumumab 、 In patient 、 Medicine 、 Internal medicine 、 Second line treatment